Crizotinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-CRIZOTINIB |
|---|---|
| Type | Drug |
| Aliases | XalkoriКризотиніб |
| Status | pending_clinical_signoff |
| Diseases | DIS-ALCL DIS-IMT |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | 1st-generation ALK / ROS1 / MET inhibitor |
|---|---|
| Mechanism | Multi-target TKI active in ALK, ROS1, and MET-driven NSCLC. Largely supplanted by alectinib/lorlatinib for ALK and entrectinib for ROS1, but retains role in ROS1+ NSCLC where access to newer agents limited. |
| Typical dosing | 250 mg PO BID. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
ROS1-positive NSCLC standard 1L when entrectinib unavailable. Largely 2L+ for ALK now.
Used By
Regimens
REG-CRIZOTINIB-ALCL- Crizotinib 250 mg PO BID continuous — r/r ALK+ ALCLREG-CRIZOTINIB-IMT- Crizotinib monotherapy (ALK-fusion-positive inflammatory myofibroblastic tumor)